Overactive Bladder With Urge Urinary Incontinence Therapeutics
1. Gemtesa patent expiration
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (bph); Treat...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8247415 | SUMITOMO PHARMA AM | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2034
(8 years from now) | |
| US8653260 | SUMITOMO PHARMA AM | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
Apr, 2029
(3 years from now) | |
| US12180219 | SUMITOMO PHARMA AM | Process for preparing beta 3 agonists and intermediates |
Mar, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357636 | SUMITOMO PHARMA AM | NA |
May, 2042
(16 years from now) | |
| US12102638 | SUMITOMO PHARMA AM | Use of vibegron to treat overactive bladder |
Mar, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2025 |
| New Indication(I-955) | Dec 18, 2027 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 23 December, 2024
Market Authorisation Date: 23 December, 2020
Dosage: TABLET
More Information on Dosage
GEMTESA family patents
2. Toviaz patent expiration
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
TOVIAZ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(3 years ago) | |
| US7384980 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US7985772 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US7855230 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US8338478 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
|
US6858650 (Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(3 years ago) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(1 year, 4 months from now) | |
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(1 year, 4 months from now) | |
| US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(1 year, 4 months from now) | |
|
US7807715 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(1 year, 10 months from now) | |
|
US8088398 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(1 year, 10 months from now) | |
|
US8501723 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2013 |
| New Indication(I-861) | Jun 17, 2024 |
| Pediatric Exclusivity(PED) | Dec 17, 2024 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
NCE-1 date: 18 December, 2023
Market Authorisation Date: 31 October, 2008
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TOVIAZ before it's drug patent expiration?
More Information on Dosage
TOVIAZ family patents